FF/GW642444 Inhalation Powder
112206
Phase 3 small_molecule completed
Quick answer
FF/GW642444 Inhalation Powder for Pulmonary Disease, Chronic Obstructive is a Phase 3 program (small_molecule) at GlaxoSmithKline with 2 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Pulmonary Disease, Chronic Obstructive
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed